AEON BIOPHARMA INC (AEON) Stock Price & Overview

NYSEARCA:AEONUS00791X2099

Current stock price

0.985 USD
0 (-0.45%)
Last:

The current stock price of AEON is 0.985 USD. Today AEON is down by -0.45%. In the past month the price decreased by -9.63%. In the past year, price increased by 111.37%.

AEON Key Statistics

52-Week Range0.375 - 1.45
Current AEON stock price positioned within its 52-week range.
1-Month Range0.9601 - 1.3295
Current AEON stock price positioned within its 1-month range.
Market Cap
36.598M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-5.98
Dividend Yield
N/A

AEON Stock Performance

Today
-0.45%
1 Week
-7.08%
1 Month
-9.63%
3 Months
-11.26%
Longer-term
6 Months +21.60%
1 Year +111.37%
2 Years -99.88%
3 Years N/A
5 Years N/A
10 Years N/A

AEON Stock Chart

AEON BIOPHARMA INC / AEON Daily stock chart

AEON Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to AEON. When comparing the yearly performance of all stocks, AEON is one of the better performing stocks in the market, outperforming 89.78% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AEON Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AEON. Both the profitability and financial health of AEON have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AEON Earnings

Next Earnings DateN/A
Last Earnings DateNov 14, 2025
PeriodQ3 / 2025
EPS Reported-$0.19
Revenue Reported
EPS Surprise 56.68%
Revenue Surprise %

AEON Forecast & Estimates

8 analysts have analysed AEON and the average price target is 5.3 USD. This implies a price increase of 438.48% is expected in the next year compared to the current price of 0.985.


Analysts
Analysts82.5
Price Target5.3 (438.07%)
EPS Next Y-101.18%
Revenue Next YearN/A

AEON Financial Highlights

Over the last trailing twelve months AEON reported a non-GAAP Earnings per Share(EPS) of -5.98. The EPS increased by 99.01% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.64M
Industry RankSector Rank
PM (TTM) N/A
ROA -14.03%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%95.6%
Sales Q2Q%N/A
EPS 1Y (TTM)99.01%
Revenue 1Y (TTM)N/A

AEON Ownership

Ownership
Inst OwnersN/A
Shares37.16M
Float10.90M
Ins OwnersN/A
Short Float %2.55%
Short Ratio1.99

AEON Latest News, Press Relases and Analysis

About AEON

Company Profile

AEON logo image AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.

Company Info

IPO: 2021-10-08

AEON BIOPHARMA INC

4040 Macarthur Boulevard, Suite 310

Newport Beach CALIFORNIA US

Employees: 6

AEON Company Website

AEON Investor Relations

Phone: 19492844555.0

AEON BIOPHARMA INC / AEON FAQ

Can you describe the business of AEON BIOPHARMA INC?

AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.


What is the stock price of AEON BIOPHARMA INC today?

The current stock price of AEON is 0.985 USD. The price decreased by -0.45% in the last trading session.


What is the dividend status of AEON BIOPHARMA INC?

AEON does not pay a dividend.


How is the ChartMill rating for AEON BIOPHARMA INC?

AEON has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the market cap for AEON BIOPHARMA INC?

AEON BIOPHARMA INC (AEON) has a market capitalization of 36.60M USD. This makes AEON a Nano Cap stock.